Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane

(Houston -- June 11, 2004) US Oncology (Nasdaq: USON) announced that data presented this week by a network physician at the American Society of Clinical Oncology annual meeting demonstrate that the investigational drug AbraxaneTM (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol) and/or docetaxel (Taxotere).

Based on analysis to date, results showed a 15 percent (95% CI: 8-22%) overall response rate in 106 patients who received Abraxane 100 mg/m2 administered weekly over 30 minutes a day without premedication for three weeks followed by one week of rest, with a 38 percent probability of surviving 12 months. Additionally, 40 percent of patients were free of disease progression for as long as four months, and almost 30 percent for as long as six months. Ninety-one percent of patients were able to receive the full dose throughout the study without dose reduction.

Joanne Blum, M.D., PhD., a US Oncology Principal Investigator at Texas Oncology PA (TOPA), who practices at Charles A. Sammons Cancer Center, Baylor University Medical Center in Dallas, Texas, presented the update. Charles A. Sammons Cancer Center was one of 38 US Oncology affiliated practices that had patients participate in the Abraxane clinical trial.

All patients in the trial, sponsored by American Bioscience, Inc., had progressive metastatic breast cancer while being treated with Taxol or Taxotere in the metastatic setting, or had a relapse within 12 months of adjuvant taxane therapy. The patient population studied had a poor prognosis with 91 percent having visceral (lung and liver) disease, 65 percent with more than three metastatic sites and 88 percent demonstrating ongoing tumor growth while on Taxol or Taxotere.

"The activity of Abraxane and the tolerance of the weekly reg

Contact: Melyssa Weible
HealthStar PR

Page: 1 2

Related biology news :

1. Breastfeeding decreases infant mortality
2. Breast cancer study suggests role for tissue in carcinogenesis
3. Breast self examination increases womens concerns but has no effect on mortality
4. Breast cancer follow-ups no longer guess-work thanks to new physics research
5. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
6. The 4th European Breast Cancer Conference (EBCC4)
7. Breast cancer susceptibility genes play role in DNA repair
8. Breast cancer can be reversed in laboratory mice, scientists report
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Breast fluid a better option for detecting cancer
11. Breastfeeding may compensate for harmful effects of smoking during pregnancy

Post Your Comments:

(Date:11/27/2019)... ... November 26, 2019 , ... Smile Glen Ellyn dentists, Drs. ... Invisalign® treatment. Invisalign orthodontics uses a series of clear, virtually invisible ... known as malocclusion, present both functional and cosmetic concerns. Functionally, crooked teeth ...
(Date:11/27/2019)... ... November 27, 2019 , ... ... hand-held device, equipped with surface electromyography (sEMG) sensors that measure and display muscle ... of the specific muscles being targeted for treatment. Both patient and therapist can ...
(Date:11/20/2019)... ... November 20, 2019 , ... BioInformatics Inc., part of Science and Medicine ... announced the winners of the Life Science Industry Awards for the most innovative new ... Awards – Innovation: , Most Innovative New Product – Cell Biology, ...
Breaking Biology News(10 mins):
(Date:11/5/2019)... ... ... German Shepherd, was demonstrating signs of osteoarthritis in April 2019. He was lame and ... willingness to play were normal, it was clear that he was in pain. , Ole’s ... and Referral Center in San Diego, California. Dr. Mullen is an experienced VetStem ...
(Date:11/2/2019)... NEW YORK (PRWEB) , ... October 31, 2019 ... ... just been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s ... data. This new tool allows researchers to quickly uncover relationships between genes, diseases, ...
(Date:10/29/2019)... ... ... CaroGen Corporation , a biotechnology company, today announced three distinguished additions to ... MD, of Brown University , Dr. Steve Projan, PhD, FAAM, formerly of ... Wayne State University, formerly a professor at Yale University School of Medicine ...
(Date:10/26/2019)... ... , ... Sparks Marketing Group, Inc. (Sparks) announced ... healthcare-specific marketing firm, to strengthen the agency’s growing focus on the healthcare vertical ... in pharma, bio-therapeutics, medical device and healthcare technologies currently account for a large ...
Breaking Biology Technology:
Cached News: